Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

yFMT

Phase 1Small molecule

TThe First Affiliated Hospital of Xiamen University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bowel CancerNot yet recruiting

Bowel CancerPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Bowel Cancer

NCT07486492

Clinical

Trials by Indication[1]

Bowel Cancer1 trial

Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 1·NCT07486492·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for yFMT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — yFMT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for yFMT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Xiamen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThe First Affiliated Hospital of Xiamen University

Related News